Pharmacokinetic assessment of peramivir in a hospitalized adult undergoing continuous venovenous hemofiltration

Annals of Pharmacotherapy

Volumn 45, Issue 12, 2011, Pages

  Scheetz, Marc H ^a,b   Griffith, Milena M ^a,b   Ghossein, Cybele ^c   Hollister, Alan S ^d   Ison, Michael G ^c  

^a MIDWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d BIOCRYST PHARMACEUTICALS INC   (United States)

Author keywords

CVVH; Influenza A; Peramivir; Pharmacokinetics

Indexed keywords

OSELTAMIVIR; PERAMIVIR; SIALIDASE INHIBITOR;

ACUTE KIDNEY FAILURE; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; CASE REPORT; CHILL; CONTINUOUS HEMOFILTRATION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DYSPNEA; FLOW RATE; HOSPITALIZATION; HUMAN; INFLUENZA; MALE; MYALGIA; NOSE SECRETION; PHARMACOKINETICS; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ACUTE KIDNEY INJURY; ADOLESCENT; CYCLOPENTANES; GUANIDINES; HEMOFILTRATION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; OSELTAMIVIR;

EID: 83155182919     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q437     Document Type: Article

References (20)

1. Sidwell RW, Smee DF, Huffman JH, et al. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201. Antimicrob Agents Chemother 2001;45:749-57. DOI 10.1128/AAC.45.3.749-757.2001
2. Ison MG, McGeer AJ, Hui DS, et al. Safety and efficacy of multiple-day treatment with intravenous peramivir or oral oseltamivir in hospitalized adults with acute influenza. Presented at: XI International Symposium on Respiratory Viral Infections, 2009; Bangkok, Thailand.
3. Birnkrant D, Cox E. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009;361:2204-7. DOI 10.1056/NEJMp0910479
4. Arya V, Carter WW, Robertson SM. The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir. Clin Pharmacol Ther 2010;88:587-9. DOI 10.1038/clpt.2010.187
5. Intensive-care patients with severe novel influenza A (H1N1) virus infection-Michigan, June 2009. MMWR Morb Mortal Wkly Rep 2009;58:1-4.
6. Trimarci H, Greloni G, Campolo-Girard V, Rosa-Diez G. H1N1 infection and acute kidney injury in the critically ill. NDT Plus 2009;2(6):506. http://ndtplus.oxfordjournals.org/content/2/6/506.2.full.pdf (accessed 2011 Nov 4). DOI 10.1093/ndtplus/sfp142
7. Emergency use authorization of peramivir IV fact sheet for health care providers. FDA. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187811.pdf (accessed 2011 Sept 8).
8. Mancuso CE, Gabay MP, Steinke LM, Vanosdol SJ. Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza. Ann Pharmacother 2010;44:1240-9. DOI 10.1345/aph.1P031
9. Questions and answers for health care providers: renal dosing and administration recommendations for peramivir IV. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM190601.pdf (accessed 2011 Sept 8).
10. Fish DN, Teitelbaum I, Abraham E. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2005;49:2421-8. DOI 10.1128/AAC.49.6.2421-2428.2005
11. Scheetz MH, Scarsi KK, Ghossein C, Hurt KM, Zembower TR, Postelnick MJ. Adjustment of antimicrobial dosages for continuous venovenous hemofiltration based on patient-specific information. Clin Infect Dis 2006;42:436-7; author reply 7-8. DOI 10.1086/499535
12. Winter M. Basic clinical pharmacokinetics. 5th ed. Baltimore: Lippincott Williams and Wilkins, 2010.
13. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000;356:26-30. DOI 10.1016/S0140-6736(00)02430-2
14. Reetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations. Clin Pharmacokinet 1993;24:362-79.
15. Joy MS, Matzke GR, Armstrong DK, Marx MA, Zarowitz BJ. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother 1998;32:362-75. DOI 10.1345/aph.17105
16. Drusano GL, Preston SL, Smee D, Bush K, Bailey K, Sidwell RW. Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for oncedaily dosing. Antimicrob Agents Chemother 2001;45:2115-8. DOI 10.1128/AAC.45.7.2115-2118.2001
17. Brown AN, Bulitta JB, McSharry JJ, et al. Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model. Antimicrob Agents Chemother 2011;55:1747-53. DOI 10.1128/AAC.01629-10
18. Thomas B, Hollister AS, Muczynski KA. Peramivir clearance in continuous renal replacement therapy. Hemodial Int 2010;14:339-40. DOI 10.1111/j.1542-4758.2010.00451.x
19. Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009;29:562-77. DOI 10.1592/phco.29.5.562
20. Bazan JA, Bauer KA, Hollister AS, et al. Peramivir pharmacokinetics in two critically ill adults with 2009 H1N1 influenza A concurrently receiving continuous renal replacement therapy. Pharmacotherapy 2010;30:1016-20. DOI 10.1592/phco.30.10.1016